Urgent intervention requiredRevised from D (50/100) after skill-informed audit. Key additions: Consent Mode v2 gap, missing ad extensions, bidding mismatch.
Current ROAS
1.36x
Current CPA
GBP 31
Hard savings done
GBP 5,298/mo
Total improvement est.
GBP 15,762/mo
Health Score Breakdown
Conversion Tracking (25%)
25/100
Wasted Spend (20%)
55/100
Account Structure (15%)
45/100
Keywords & QS (15%)
30/100
Ads & Assets (15%)
35/100
Settings & Targeting (10%)
40/100
Final Review List
This section is designed for a voice-driven walkthrough. Each item has a checkbox, a number, and a clear action. Read each item aloud, discuss with Claude via mic, then tick off when decided. Items are grouped by decision type and priority.
Section A: Hard Blockers (Must fix before ANY new campaigns)
These items block all forward progress. No new campaigns, creative, or scaling until resolved.
A1
Audit all 29 conversion actions HARD BLOCKER
29 enabled conversion actions with likely double-counting. All Smart Bidding is flying blind. Reduce to Purchase-only as Primary per market. YouTube follow-on views already fixed to Secondary -- 28 remain unaudited. Action: Open Google Ads > Goals > Conversions. Audit every action. Set only "Purchase" as Primary. Everything else to Secondary or remove. Question for review: Do we know which conversion actions are currently set as Primary?
A2
Verify Consent Mode v2 on DE + FR stores LEGAL REQUIREMENT
Mandatory for EU/EEA since July 2025. Not mentioned in any of 55 files. Without it: 90-95% conversion data loss in DE/FR AND potential GDPR enforcement. Action: Check brainzyme.de and brainzyme.fr for consent banner implementation. Verify in Google Tag Assistant. Question for review: Is there a cookie consent banner on the DE and FR stores? Is it integrated with Google consent signals?
A3
Live-verify all 64 landing page URLs 5-MINUTE FIX
File 11 has 64 URLs from Google Docs extraction, not live crawling. Earlier check found 6/9 guessed UK URLs returning 404. Action: Batch crawl all 64 URLs. Flag any non-200 responses. Fix or redirect before campaigns go live. Question for review: Can I run a batch URL check now?
Section B: Compliance Fixes (Must fix before deploying new ad copy)
Regulatory and legal risks. Some could result in account suspension or legal action.
B1
Remove FR Ritaline from paid ads CRITICAL / DGCCRF
UFC-Que Choisir directly named Brainzyme in "Attention aux pilules anti-TDAH". Files contradict: 09-FR says NEVER use Ritaline in paid ads, but 13-FR includes a full Ritaline Alternative PMax asset group (AG3) and file 14 includes Search RSA Campaign 6. Decision needed: Remove AG3 from FR PMax plan AND hold Campaign 6 from Search RSA plan? Keep organic/SEO presence only? My recommendation: Yes, remove both. Anti-fatigue mentale is the better play with zero regulatory risk.
B2
Remove DE "Ohne Nebenwirkungen" HWG VIOLATION
"Without side effects" is a medical claim under Heilmittelwerbegesetz. Found in DE PMax AG2 headlines. Action: Replace with "Pflanzlich & Gut Vertraglich" (Plant-Based & Well-Tolerated). Decision needed: Approve replacement copy?
B3
Fix FR "Traitement Naturel Fatigue" DGCCRF RISK
"Traitement" = "treatment" in French. DGCCRF may consider this a medical claim for a supplement. Action: Change to "Solution Naturelle Anti-Fatigue" or "Soutien Naturel Concentration". Decision needed: Which replacement do you prefer?
B4
Fix US Elite pricing ($29 shown, actual ~$60) MISLEADING
Price Extensions in 13-US list Focus Elite at "$29" when it's GBP 47 (~$60+). Action: Correct to actual USD price or remove Elite from price extensions. Decision needed: What is the correct USD price for Focus Elite?
B5
Verify UK "#1 Rated" claim ASA SUBSTANTIATION
"UK's #1 Rated Focus Supplement" needs ASA-compliant substantiation. Is 4.74/5 genuinely the highest verified rating in category? Decision needed: Can we document evidence? Or soften to "One of the UK's Highest-Rated"?
B6
Review ADHS usage in German ad copy MONITOR
Strategy bans "ADHD" (English) and "TDAH" (French) but uses "ADHS" (German) freely in headlines and PMax asset groups. Legal under current HWG interpretation but BfArM has been tightening. Decision needed: Accept the risk or apply the same ban? Consider consulting a German health advertising specialist?
Section C: Decisions Already Made (Confirm or Revisit)
These changes have already been executed. Confirm you're happy with each, or flag for rollback.
C1
Demand Gen pause (7 campaigns) DONE -- GBP 3,476/mo saved
0.21x ROAS across all 7 campaigns. GBP 5,968/mo spend for 24.6 conversions at GBP 242 CPA. Pure waste. Question: Confirm happy to keep all 7 paused?
C2
US reduction (Adderall paused, USA halved) DONE -- GBP 1,636/mo saved
PMax US Adderall: 0.01x ROAS, GBP 6,444 CPA. PMax USA: 0.95x ROAS, budget cut to GBP 30/day. Question: Confirm US brand-defence-only strategy?
Phrase-match negatives for medication, prescription, Ritalin, Adderall, etc. Kids/children intentionally excluded (FOCUS ORIGINAL works for 10-15). Question: Confirm negative keyword list is correct?
C4
DE brand CPC ceiling raised to GBP 2.00 DONE
Was GBP 1.00 with 10.9x ROAS and 52% impression share. Leaving profitable impressions on the table. Question: Confirm happy with GBP 2.00 ceiling?
C5
ROAS guardrails rolled back CORRECT ROLLBACK
200% Target ROAS applied to UK/DE/FR PMax, then rolled back same day. PMax FR dropped from 1.49x to 0.86x. Lesson: creative refresh must come BEFORE guardrails. Question: Confirm we wait until post-creative-refresh (Week 5+) to re-apply?
C6
US Brand Search reverted to Target Impression Share DONE (by you)
CPA had collapsed from GBP 2.47 to GBP 63.40 after being switched to Maximize Conversions. Question: Confirm this is stable now?
Section D: Strategy Decisions (Approve or Modify)
These are proposed strategies that need your sign-off before implementation.
D1
DE market: aggressive scaling (zero competition window)
Brainzyme is the ONLY brand running Google Ads on focus/nootropic keywords in Germany. BRAINEFFECT pivoted to gut health. Proposed: 2 new Search campaigns (Ritalin/ADHS + Konzentration), PMax DE refresh, budget increase to 41% allocation. Decision needed: Approve DE as Priority #1 market for scaling? Approve 41% budget allocation?
D2
FR: pivot to anti-fatigue mentale as primary positioning
Dual-track: shift from Ritaline (60% now -> 20% by M6) to anti-fatigue mentale (40% -> 80%). 52% of French adults report fatigue as #1 complaint. Zero PPC competition on "anti fatigue mentale". Decision needed: Approve the pivot timeline? Comfortable with Ritaline organic-only approach?
D3
UK problem-aware Search campaign
Targeting "brain fog help", "can't concentrate", "mental fatigue" at GBP 0.50-1.50 CPC (vs GBP 3-4 for generic supplement terms). 7 ad groups. Decision needed: Approve keywords and ad groups? Which landing pages for each group?
D4
Budget allocation: UK 45% / DE 41% / FR 12% / US 2%
Based on 70/20/10 framework (proven/scaling/testing). Total GBP 20,000/mo. UK and DE are proven markets. FR is scaling. US is defence-only. Decision needed: Approve these percentages? Any adjustments?
D5
Creative direction: scientific/medical aspirational, NOT leafy/botanical
You previously confirmed leafy imagery was tested and failed. Magazine editorial aesthetic. Premium, clean, aspirational. 42 images generated and awaiting review. Decision needed: Review the 42 generated images. Approve, reject, or request revisions?
Section E: Quick Wins (High ROI, low effort)
These can be done quickly and have immediate impact.
E1
Connect DE product feed USER ACTION NEEDED
PMax DE Ritalin (2.43x ROAS, GBP 14.84 CPA) and PMax DE Austria Ritalin (2.04x ROAS) both sitting at GBP 0.01/day because product feed isn't connected. Easiest revenue recovery in the account -- est. +GBP 2,700/mo. Action: Connect Shopify product feed to Google Merchant Center for DE store. Question: Do you have access to Google Merchant Center? Is the DE product feed already configured in Shopify?
E2
Add RSA to Focus & Attention ad group COPY READY
Ad group created with 10 keywords but no RSA ad. Keywords without ads don't serve. Copy exists in file 04. Action: Claude can deploy the RSA copy via API (ad group creation works, just campaign creation is broken). Question: Approve deploying the RSA ad from file 04?
E3
Add ad extensions to ALL Search campaigns NEW FINDING
Sitelinks, callouts, structured snippets, and image extensions are entirely missing from all 55 files and from the account. Per benchmarks: high QS from extensions = 50% CPC discount. Low QS = 400% CPC premium. Action: Write and deploy sitelinks (4+), callouts (4+), structured snippets for UK, DE, FR, US. Question: Approve me writing the extension copy? Specific sitelinks you want?
File 10 Image 8 specifies "beaker, clinical aesthetic" but brand exclusion rules ban beakers. Action: Replace with peer-reviewed journal, ingredient close-up on marble, or similar. Question: Approve replacement concept?
Section F: Gaps Identified (No action yet -- need discussion)
These are structural gaps found during audit. Each needs a decision on whether/when to address.
F1
Bidding strategy mismatch
Per ads-budget decision tree: campaigns with <30 conversions/month should use Maximize Clicks (with CPC cap), not Maximize Conversion Value. Several PMax campaigns are on MaxConvValue with <30 monthly conversions. May be contributing to erratic bidding. Question: Should we switch low-volume campaigns to Maximize Clicks? Or wait until conversion tracking is fixed first?
F2
PMax brand exclusions not configured
Google audit G07/G-PM3: PMax without brand exclusions cannibalises brand Search. Brand Search is 8.5-10.9x ROAS. If PMax is taking those conversions, the true non-brand PMax ROAS is even lower than reported. Question: Should we configure brand exclusions in PMax? This would give a true picture of non-brand PMax performance.
F3
US landing page quality
Every US page has the same H1 ("Focus Supplements Backed by Science"), zero visible reviews, no content differentiation. Any US Search campaign will have poor Quality Scores until fixed. Question: Is fixing US landing pages worth the effort given US is brand-defence-only? Or deprioritise?
F4
Healthcare remarketing risk in PMax
Google prohibits remarketing for health services. PMax campaigns may be doing this via audience signals (custom segments, remarketing lists). Question: Should we audit PMax audience signal configuration? Risk of account suspension if non-compliant.
F5
MER (Marketing Efficiency Ratio) not tracked
Blended efficiency across all channels is the true north metric. Current blended ROAS ~2.1x but true MER (including organic, email, etc.) unknown. Question: Do we want to set up MER tracking? Requires total revenue data from Shopify + total marketing spend.
F6
UK/US competitor conquest campaigns dropped
Strategy mentions UK and US competitor campaigns ("Mind Lab Pro alternative", "Alpha Brain alternative") but they're absent from keyword lists, ad copy, and deployment specs. Appears intentionally dropped after you declined competitor conquesting. Question: Confirm this was a deliberate decision? Or revisit later?
Important caveat: Hard savings (GBP 5,298/mo) are real and already achieved. The remaining GBP 10,464/mo depends on creative refresh restoring historical ROAS levels and DE product feed being connected. Plausible but not guaranteed. See the interactive projections dashboard for scenario modelling.
DE product feed. RSA for Focus & Attention. Ad extensions (all campaigns). Compliance copy fixes.
Product feed needs Shopify access
3-4
Creative
PMax creative refresh (all markets). Deploy 5 new Search campaigns via UI.
Image approval from you
5+
Scale
Re-apply ROAS guardrails. Launch FR anti-fatigue + DE Konzentration. Scale DE budget.
2+ weeks post-creative baseline
Section I: Market Strategy Summary
UK -- 45% budget (GBP 9,180/mo)
"Can't concentrate? There's a plant-powered solution."
Problem-aware keywords at GBP 0.50-1.50 CPC. Brand Search 9.01x ROAS. PMax UK creative refresh urgent (24mo old). Brain Quiz does NOT convert for paid traffic.
DE -- 41% budget (GBP 8,364/mo) -- BIGGEST OPPORTUNITY
"Konzentration naturlich steigern"
ONLY brand bidding in Germany. 2 new Search campaigns ready. PMax DE Ritalin at 2.43x ROAS blocked on product feed. "Ohne Nebenwirkungen" must be removed (HWG).
FR -- 12% budget (GBP 2,856/mo)
"Anti-fatigue mentale -- concentration naturelle"
Pivot from Ritaline to anti-fatigue. 500-1,500 monthly searches, zero PPC competition. No paid Ritaline ads. Fix "Traitement" language.
US -- 2% budget (GBP 360/mo) -- DEFENCE ONLY
Brand search only. No expansion.
GBP 30/day brand search. Fix Elite pricing error. Verify conversion tag on US checkout. All US pages have identical H1, zero reviews.
Generated 1 April 2026 | Claude Opus 4.6 | 74-check audit framework | 6 skills loaded
Interactive version: 02-AUDIT-DASHBOARD.html (Projections tab for scenario modelling)